Ketamine therapy uses sub-anesthetic doses of ketamine, a drug originally developed as a surgical anesthetic in the 1960s, to treat severe depression, PTSD, and certain other psychiatric conditions. Unlike conventional antidepressants that can take weeks to show effects, ketamine can produce measurable mood improvements within hours, working through a fundamentally different brain mechanism that promotes rapid new connections between neurons. The science behind this speed, and the practical reality of receiving ketamine treatment today, involves more nuance than most summaries let on.
From Operating Room to Psychiatric Clinic
Ketamine entered clinical practice in the 1960s as an anesthetic and has remained on the World Health Organization’s list of essential medicines for surgical use ever since.1PubMed Central. Ketamine: 50 Years of Modulating the Mind Its psychiatric potential stayed largely unexplored until researchers in the early 2000s began publishing evidence that a single low-dose infusion could rapidly relieve depression in patients who had not responded to standard medications. That discovery set off a wave of research, and by 2019 the U.S. Food and Drug Administration had approved an intranasal spray of esketamine, one of ketamine’s two mirror-image molecular forms, specifically for treatment-resistant depression. The same approval followed in Europe later that year.2PubMed. A historical review of antidepressant effects of ketamine and its enantiomers Meanwhile, off-label intravenous ketamine clinics have proliferated across the United States, creating a two-track system where the approved nasal spray and the generic IV version coexist under very different regulatory and insurance frameworks.
How Ketamine Works in the Brain
Most conventional antidepressants target serotonin or norepinephrine, adjusting the levels of those chemical messengers over weeks. Ketamine takes a different route entirely. It blocks a receptor called NMDA, which normally responds to glutamate, the brain’s most abundant excitatory chemical signal. Paradoxically, blocking this receptor triggers a burst of glutamate release in the prefrontal cortex, the region involved in planning, decision-making, and emotional regulation. Human imaging studies have confirmed this, showing roughly a 13% increase in a marker of glutamate cycling in the prefrontal cortex after ketamine administration compared to placebo.3PubMed Central. The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects Animal studies have corroborated this finding, showing that ketamine increases the release of glutamate at synapses in the cortex.4PubMed Central. Glutamate Deregulation in Ketamine-Induced Psychosis—A Potential Role of PSD95, NMDA Receptor and PMCA Interaction
That glutamate surge is only the first step. The downstream effect is what researchers believe drives the antidepressant response: the rapid growth of new dendritic spines, the tiny protrusions on brain cells where synaptic connections form. Depression is associated with a loss of these spines in the prefrontal cortex. Ketamine reverses that loss. In mouse models, a single dose of ketamine selectively rescued spines that had been eliminated by chronic stress, restoring coordinated neural activity patterns linked to motivated behavior.5PubMed Central. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation This spine regrowth also occurs in the hippocampus, a brain region central to memory and emotional processing.6PubMed Central. (R)-Ketamine Rapidly Ameliorates the Decreased Spine Density in the Medial Prefrontal Cortex and Hippocampus of Susceptible Mice After Chronic Social Defeat Stress Research indicates this spine formation is triggered through dopamine signaling and proceeds fast enough to match the timing of ketamine’s behavioral effects.7PubMed Central. Ketamine Rapidly Enhances Glutamate-Evoked Dendritic Spinogenesis in Medial Prefrontal Cortex Through Dopaminergic Mechanisms
A computational modeling study captured the distinction neatly: while SSRIs work by gradually optimizing existing neural connections over weeks, ketamine works by structurally rebuilding connections that depression has pruned away.8PubMed Central. Divergent Mechanisms of Antidepressant Efficacy: A Unified Computational Comparison of Synaptogenesis, Stabilization, and Tonic Inhibition in a Model of Depression That structural rebuilding explains the speed, but it also explains one of ketamine’s limitations: without repeated treatment, those new connections can fade.
What Happens at the Network Level
Beyond individual synapses, ketamine reshapes how entire brain networks communicate. A collection of brain regions called the default mode network, which is active during self-referential thinking and rumination, shows abnormal connectivity patterns in depression. Brain imaging studies have found that ketamine normalizes connectivity between the insula (a region involved in interoception and emotional awareness) and the default mode network in people with major depression. This normalization was visible two days after a single infusion, though it had reversed after ten days.9PubMed Central. Default mode connectivity in major depressive disorder measured up to 10 days after ketamine administration A separate placebo-controlled study using simultaneous brain imaging and EEG found that ketamine decreased connectivity in the medial prefrontal cortex while increasing it in parietal regions, effectively shifting the balance of the default mode network.10PubMed Central. Ketamine effects on default mode network activity and vigilance: A randomized, placebo-controlled crossover simultaneous fMRI/EEG study
This temporary rewiring may help explain why patients often describe ketamine’s effect as a “break” from the cycle of negative self-focused thinking. The rumination-heavy default mode gets quieted while other circuits come online. The challenge, reflected in the imaging data, is that this network reset tends to fade within a week or two without additional treatment.
The Opioid System Puzzle
One of the more contested questions in ketamine science is whether the drug’s antidepressant effects depend partly on the brain’s opioid system. A striking study at Stanford found that when patients were pretreated with naltrexone, a drug that blocks opioid receptors, ketamine’s antidepressant effect was dramatically blunted. Depression scores dropped by about 22 points with ketamine alone but only about 6 points when naltrexone was given first.11PubMed Central. Opioid Receptor Antagonism Attenuates Antidepressant Effects of Ketamine That raised alarms about whether ketamine might work partly like an opioid.
Follow-up research in rats added an important clarification: while opioid receptor signaling appears to be necessary for ketamine’s antidepressant action, activating opioid receptors alone does not reproduce the effect, and ketamine does not create the same rewarding “high” as an opioid drug. The researchers concluded that the opioid system is “permissive” rather than the primary driver, meaning both the NMDA-blocking and opioid pathways need to be intact for the full antidepressant response to occur.12PubMed Central. Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents This distinction matters because it suggests ketamine is not simply a disguised opioid, but its mechanism does overlap with the opioid system in ways that demand caution.
Esketamine, Arketamine, and Racemic Ketamine
Ketamine as used in anesthesia is a 50/50 mix of two mirror-image molecules: S-ketamine (esketamine) and R-ketamine (arketamine). They are chemically identical but oriented differently in three-dimensional space, and they behave differently in the body. Esketamine binds more tightly to the NMDA receptor and provides roughly three times the painkilling potency and one and a half times the anesthetic strength of arketamine.13PubMed Central. Ketamine, Esketamine, and Arketamine: Their Mechanisms of Action and Applications in the Treatment of Depression and Alleviation of Depressive Symptoms Esketamine is the form approved by the FDA as a nasal spray (brand name Spravato), administered in certified clinics alongside an oral antidepressant. Its antidepressant effects typically become evident within 24 hours of administration.14Pharmacotherapy in Psychiatry and Neurology. A review of the antidepressant effects of esketamine and arketamine in treatment-resistant depression
Arketamine, the other half, is generating growing interest because it appears to produce fewer dissociative and psychotomimetic side effects while still showing antidepressant promise in preliminary studies.15PubMed. Arketamine: a scoping review of its use in humans It has also shown potential in neurological conditions beyond depression. However, arketamine has only been tested in small patient groups so far, and no large randomized trials have been completed. It remains an investigational compound, not a clinically available therapy.
In practice, the off-label IV ketamine infusion clinics in the U.S. use the racemic mix (both forms together), not the isolated esketamine found in the nasal spray. This creates an odd regulatory landscape where a patient can receive the generic compound off-label but without insurance coverage, while the branded esketamine spray carries FDA approval and broader formulary inclusion.
What the Clinical Evidence Actually Shows for Depression
The promise of ketamine for treatment-resistant depression is real, but it comes with important caveats about durability. A real-world study of patients with chronic treatment-resistant depression found that a single infusion was not enough to produce a response, and more than half of eventual responders met the response threshold only after the third infusion. Remission after a full course of infusions was rare, with only about 6% achieving it. And nearly all responders relapsed within one month of stopping treatment.16PubMed Central. Ketamine and chronic treatment-resistant depression: real-world practice and after relapse
This is where maintenance protocols become critical. A systematic review of maintenance ketamine therapy found that regular, scheduled dosing produced better outcomes than variable or as-needed protocols, with relapse rates of about 27% versus 46%. Being younger than 45 and having been depressed for less than two years predicted better responses.17PubMed. Efficacy and safety of ketamine maintenance therapy in treatment-resistant depression: A systematic review of treatment protocols and clinical outcomes In short, ketamine for depression is not a one-and-done treatment. It typically requires an initial series of infusions followed by ongoing maintenance, and even then, response is not guaranteed for everyone.
Ketamine for Suicidal Ideation
One of the most compelling aspects of ketamine therapy is its rapid effect on suicidal thinking. This is distinct from its general antidepressant effect. A pooled analysis of 133 patients found that at roughly four hours after a ketamine infusion, suicidal thoughts had improved significantly, and this improvement could not be fully explained by the reduction in depression and anxiety symptoms. Those mood improvements accounted for only about 19% of the change in suicidal ideation, suggesting ketamine has a direct anti-suicidal effect that goes beyond simply lifting mood.18PubMed Central. Does Ketamine Have Rapid Anti-Suicidal Ideation Effects? For emergency settings where a patient is in acute crisis, this rapid action fills a gap that no other currently approved medication can match.
PTSD, Anxiety, and Beyond
Depression is the most studied psychiatric indication, but ketamine is also being explored for post-traumatic stress disorder and anxiety disorders. A randomized controlled trial comparing ketamine to midazolam (an active placebo) in people with chronic PTSD found that 67% of the ketamine group responded to treatment versus 20% in the control group. Among responders, the median time before symptoms returned was about 28 days after a two-week course of infusions.19PubMed. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder A meta-analysis of ketamine for PTSD confirmed improvements on standard symptom measures, though it noted high variability across studies.20PubMed Central. Effectiveness of Ketamine for the Treatment of Post-Traumatic Stress Disorder – A Systematic Review and Meta-Analysis
For refractory anxiety disorders, the picture is earlier-stage but promising. Single doses of ketamine have demonstrated fast-acting anxiolytic effects that can persist for up to a week after the main psychoactive effects wear off.21PubMed Central. Ketamine treatment for refractory anxiety: A systematic review Ketamine’s role in chronic pain management, particularly for complex regional pain syndrome, is also an active area of clinical use, though the evidence base there rests on narrative reviews and smaller studies rather than large randomized trials.22PubMed Central. Ketamine for Complex Regional Pain Syndrome: A Narrative Review Highlighting Dosing Practices and Treatment Response
Combining Ketamine With Psychotherapy
A growing number of clinics offer ketamine-assisted psychotherapy, where the drug session is embedded within a structured therapeutic framework. The idea is that ketamine’s neuroplasticity-promoting and dissociative effects create a psychological window of flexibility that a therapist can leverage. A large retrospective study of this approach found that patients treated with ketamine-assisted psychotherapy for depression, anxiety, or PTSD showed clinically meaningful improvements at three months, with roughly half to three-quarters reporting a meaningful difference. Those gains were largely sustained at six months.23PubMed Central. Ketamine-Assisted Psychotherapy Provides Lasting and Effective Results in the Treatment of Depression, Anxiety, and Post-Traumatic Stress Disorder at 3 and 6 Months
A smaller study of ketamine combined with psychotherapy in a public European hospital found that after eight weeks, all participants showed reduced depression severity, with about 44% achieving at least a 50% reduction in their depression scores. Among those with suicidal ideation, slightly over half saw those thoughts resolve by treatment’s end, and only about 29% of those monitored afterward experienced a mood deterioration within three months.24PubMed Central. Ketamine Combined With Psychotherapy as a Treatment for Resistant Depression in a Public European Hospital These results hint that pairing ketamine with psychotherapy may help extend its benefits, though randomized head-to-head comparisons against ketamine alone are still needed.
Routes of Administration and How They Compare
Ketamine can be given intravenously, intranasally, orally, or by intramuscular injection, and the route matters more than you might expect. Intravenous infusion delivers the drug directly into the bloodstream, producing predictable blood levels and the strongest acute effects. Intranasal delivery (the approved esketamine spray route) gets the drug into circulation reasonably quickly but at somewhat lower concentrations. Oral ketamine undergoes extensive first-pass metabolism in the liver and gut, meaning a much smaller fraction reaches the brain.25PubMed. Brain penetration of ketamine: Intranasal delivery VS parenteral routes of administration
These pharmacokinetic differences translate into clinical differences. A meta-analysis found that all three routes produced antidepressant effects for mood disorders, but the magnitude and timing varied. Intranasal and IV ketamine showed large effect sizes in the first 24 hours to a week, while oral ketamine’s effects were more modest but appeared to extend through three to four weeks.26PubMed. The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis The speed at which ketamine enters the bloodstream also predicts side effects: faster entry means more dissociation and greater blood pressure spikes. A systematic review found a very strong correlation between the ratio of ketamine to its main metabolite (which reflects how quickly the drug is hitting the system) and the intensity of dissociative symptoms and blood pressure changes.27PubMed. Influence of formulation and route of administration on ketamine’s safety and tolerability: systematic review
Side Effects and Safety Concerns
At therapeutic doses administered in a clinical setting, ketamine’s most common side effects are transient: dissociation (a feeling of detachment from your body or surroundings), nausea, dizziness, and temporary increases in blood pressure. These typically resolve within a couple of hours. Cardiovascular monitoring during and after administration is standard practice, particularly for patients with preexisting heart conditions or high blood pressure.28PubMed Central. Safety considerations and risk mitigation strategies for ketamine use: a comprehensive review
The more serious safety concerns involve repeated or heavy use. Recreational ketamine users, who consume the drug at much higher doses and far more frequently than psychiatric patients, face a well-documented risk of bladder damage. Regular use increases the risk of cystitis symptoms by three to four times, and the resulting condition can involve bladder pain, reduced bladder capacity, and in severe cases, kidney damage. Stopping ketamine use usually improves symptoms.29PubMed Central. Ketamine-Induced Cystitis: A Comprehensive Review of the Urologic Effects of This Psychoactive Drug There are also case reports of ketamine-induced liver and bile duct damage in chronic recreational users.30PubMed Central. Ketamine-Induced Cholangiopathy With Concomitant Hemorrhagic Cystitis: An Emerging and Underrecognized Cause of Cholestasis These complications have been linked to heavy recreational use patterns rather than supervised clinical dosing, but they underscore why long-term maintenance therapy needs careful monitoring.
A systematic review focused specifically on addiction risk during depression treatment found that medically supervised ketamine use carries a relatively low risk, provided that dosing is controlled, administration happens in a clinical environment, and patients with a history of substance use disorders are carefully screened beforehand.31PubMed. Is there a risk of addiction to ketamine during the treatment of depression? A systematic review of available literature Ketamine does have dissociative properties that give it abuse potential, but the clinical data to date have not shown a pattern of patients escalating their use or developing dependence under supervised protocols.
What Ketamine Does to Thinking and Memory
A reasonable concern for anyone considering ketamine therapy is whether it will impair cognitive function. During a session, the answer is yes, temporarily. A study of IV ketamine in people with depression or PTSD found declines in attention, verbal memory, and executive function at two hours after infusion. The good news: all of those effects resolved by the next day. Working memory, interestingly, was not affected at all during the infusion.32Translational Psychiatry. Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder
More encouraging still, a study tracking cognitive performance across a series of ketamine infusions in treatment-resistant depression found that after the first and fourth infusions, patients actually showed improvements in processing speed, working memory, inhibition, and overall fluid cognition. The cognitive improvements in processing speed and overall fluid cognition persisted through follow-up, and they appeared to be statistically independent of the drug’s antidepressant effects.33PubMed. Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression This suggests that the brain-rebuilding properties of ketamine may benefit cognition alongside mood, though more research is needed to confirm this across larger groups.
The Cost and Insurance Problem
Even if ketamine therapy works for someone, paying for it is another obstacle entirely. The insurance landscape creates a paradox: IV ketamine, the generic drug with two decades of evidence behind it, is typically not covered by insurance because it lacks an FDA indication for depression. Insurers label it “experimental.” Meanwhile, the branded esketamine nasal spray, which is FDA-approved, does appear on insurance formularies. A review of Ohio health insurance plans found that IV ketamine was covered by zero Marketplace or Medicaid plans for depression, while intranasal esketamine was included on about 73% of Marketplace and all Medicaid formularies.34Journal of Psychiatric Practice. Formulary Coverage of Esketamine and Ketamine for Depression in Ohio Health Insurance Marketplace and Medicaid Plans
The irony is that from the patient’s perspective, esketamine with insurance coverage tends to be less costly than paying out-of-pocket for IV ketamine, even though the underlying drug is far cheaper as a generic.35PubMed. Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates Out-of-pocket IV ketamine infusions typically run several hundred dollars per session, and a full initial course involves multiple sessions over two to three weeks, followed by maintenance infusions. For many patients, the total cost is a significant barrier, and it creates a situation where access to ketamine therapy depends heavily on geography, income, and the specific details of your insurance plan.
Predicting Who Will Respond
Not everyone responds to ketamine, and researchers are actively working to identify biomarkers that could predict who will benefit before they undergo treatment. The search spans brain imaging, sleep patterns, hormone levels, immune markers, and genetic factors.36PubMed Central. Neurobiological biomarkers of response to ketamine One promising finding involves a specific region of the brain’s anterior cingulate cortex. In patients with depression, greater activity in this area during emotional stimulation predicted better antidepressant outcomes 24 hours after a ketamine infusion.37International Journal of Neuropsychopharmacology. Predicting Antidepressant Effects of Ketamine: the Role of the Pregenual Anterior Cingulate Cortex as a Multimodal Neuroimaging Biomarker Clinical predictors have also emerged: the maintenance therapy review noted that younger age and a shorter history of depression were associated with better response rates.17PubMed. Efficacy and safety of ketamine maintenance therapy in treatment-resistant depression: A systematic review of treatment protocols and clinical outcomes None of these biomarkers are yet reliable enough for routine clinical use, but the field is moving toward a more personalized model where a brain scan or blood test might eventually guide treatment decisions rather than the current trial-and-error approach.